Natreon recieves more scientific backing for Phyllanthgus emblica

This marks the 12th clinical for heart healthy amla extract

Natreon, a natural ingredient research and innovation company has recently published a clinical study on Capros, its Phyllanthgus emblica fruit extract.

During a 12-week trial, Capros showed significant improvement to endothelial function, oxidative stress, immune response and lipid profile. This marks the 12th clinical trial published by Natreon for its innovative heart healthy amla extract.

Out of the 65 screened subjects, 59 eligible subjects were randomised and completed the study. The study consisted of two different dosages - 250 mg and 500 mg twice daily.

Both dosages showed significant improvement, but the 500 mg dose was significantly more efficacious. Thus, this product may be used as an adjunct to conventional therapy (lifestyle modification and pharmacological intervention) in the management of metabolic syndrome.

Dr Sanni Raju, CEO of Natreon, said: “Capros has all the attributes of being an excellent heart health product and has been consistently proven to be so in multiple clinical studies. This latest trial once again has shown the ability of Capros to improve vascular health, reduce oxidative stress, improve the lipid profile, especially by reducing the LDL and triglycerides.”

Raju said that the extract has also been shown to enhance immune response by reducing hsCRP and improving blood flow.

Capros is a totally natural and vegan edible fruit aqueous extract and when combined with its recently issued US Patent (8,962,576) on composition and methods for improving endothelial function and cardiovascular health, Capros’ solubility, stability and taste, make it an ideal heart health product for capsule, powder and beverage formations.

Companies